Previously, we reported modeling synovial sarcomas in mice by conditionally expressing the human t(X;18) translocation-derived SYT-SSX2 fusion protein in Myf5-expressing myoblasts.
Introduction
Many sarcomas, or mesenchymally-based malignancies, are associated with unique reciprocal chromosomal translocations. These translocations generate chimeric fusion proteins, the presence of which is highly specific to the related sarcoma subtype. Some examples include:
PAX3-FKHR in Alveolar Rhabdomyosarcoma, SYT-SSX in Synovial Sarcoma, and EWS-FLI in Ewing's Sarcoma (1) . Association of such specific translocation-derived fusion proteins with specific sarcomas leads to the possibility of modeling these diseases in mice by transgenic expression of the fusion product. However, such attempts are often hampered by our lack of knowledge of the cell of origin. The tumorigenic effect of an oncogene is often specific to a cell type and its microenvironment as both intra and extra-cellular factors play important role in tumorigenesis (2) . Expression of an oncogene in an inappropriate cell type or microenvironment may lead to no phenotype or tumor-unrelated phenotypes, while ubiquitous expression is often lethal. Therefore, targeting expression of the oncogene in the appropriate cell type within an appropriate microenvironment is crucial to successful tumor modeling and can be technically challenging.
Cre-LoxP based conditional system is widely used in tumor modeling to target oncogene expression to specific cell/tissue types. The most common method of delivering Cre recombinase to the target tissue is by breeding with transgenic mice expressing Cre in a tissue-specific manner. A major limitation of this strategy is that Cre (and hence the oncogene) is expressed in all or most cells in the target tissue leading to significant alteration of the entire tissue and likely affects tumorigenesis by disrupting the required interaction of the oncogene expressing cells with the 'normal' cells of the niche. A promising new development has been the establishment of Tamoxifen-inducible CreER systems that allow temporal and even quantitative control over expression in a chosen tissue by controlling nuclear entry of Cre (and hence Cre activity) by measured exposure to exogenous small molecule Tamoxifen (3).
By using a CreER based strategy we demonstrate that random, sporadic expression of SYT-SSX2 in a small subset of cells across multiple tissue types leads to the exclusive generation of synovial sarcoma-like tumors in adult mice.
Materials and methods

Animal study and Genotyping procedures
Studies involving animal subjects were approved by the University of Utah Institutional Animal Care and Use Committee and conducted strictly in accordance with the relevant protocol.
The SSM2 conditional mice, R-CreER, and the R-LacZ reporter mouse line were all genotyped with the same set of primers -Forward-WT: GTTATCAGTAAGGGAGCTGCAGTGG, Reverse-targeted: AAGACCGCGAAGAGTTTGTCCTC and Reverse -WT:
GGCGGATCACAAGCAATAATAACC. These primers yield a 302 bp band for targeted and a 415 bp band for wild type ROSA locus. Cre-expressing mice were genotyped using a pair of Cre specific primers -Forward: GGATTTCCGTCTCTGGTGTAGC and Reverse:
ACCATTGCCCCTGTTCACTATC that yield a 320 bp band.
Tamoxifen was dissolved in warm sterile corn oil at a concentration of 20mg/ml that was used to inject mice intra-peritoneally.
Histology and Immunohistochemistry
For histology, specimens were fixed overnight in 4% paraformaldehyde and embedded in paraffin wax following standard procedure. 4-8 -µm sections were cut and mounted on slides for standard Hematoxylin and Eosin (H & E) staining. Immunohistochemistry on 4 -µm sections of paraffin embedded samples was carried out by the ARUP laboratories at the University of Utah.
Counterstaining was done with hematoxylin.
β-galactosidase staining
For whole mount staining; samples were fixed in 1% PFA, 0.2% glutaraldehyde, 0.002M MgCl 2 , 0.025M EGTA and 0.02% NP-40 in 1X PBS for 2 hrs at 4 degree centigrade followed by overnight staining at RT in 0.005M K 3 Fe(CN) 6 , 0.005M K 4 Fe(CN) 6 , 0.002M MgCl2, 0.01% Nadoc, 0.02% NP-40 and X-Gal substrate in 1X PBS. Stained tissue were processed for paraffin embedding and sectioned as mentioned above. Counterstaining was carried out with nuclear red following established protocol.
Cell culture
Mouse embryonic fibroblasts were harvested by euthanizing mice and harvesting E13.5 -E14.5 embryos in a sterile environment. Extra-embryonic tissue, head, and internal organs were removed from the embryos in sterile PBS. Embryos were put in sterile tubes containing 50 ml sterile 1X PBS followed by addition of 1ml of cold 0.25% tripsin and incubated at 4 degrees overnight to allow tripsin diffusion within tissue. The next day, all solutions were removed and replaced with 0.25% tripsin solution and incubated at 37 degrees for 10-15 minutes with gentle shaking. This was followed by addition of 10%FBS + DMEM to the tube and vigorous pipetting with medium bore pipet to disrupt the tissue and plated.
Cells were maintained in media containing 10%FBS + DMEM. The production of TAT-Cre is part of a separate manuscript that is being submitted.
Imaging
Computed tomography of sacrificed mice was performed at 93 μm 3 voxel resolution using the eXplore RS Small Animal MicroCT Scanner (GE Healthcare). Images were reconstructed and visualized with the manufacturer's MicroView freeware. Fluorescent microscopy was performed using the Axiovert 200M (Carl Zeiss) microscope, image captured using the sensicam (The Cooke Corporation), and the slidebook TM image capture and analysis software (Intelligent Imaging and Innovation Inc). Light microscopy was performed using the same microscope using an Axiocam HRC camera and the Axiovision (4.6) image capture and analysis software.
Microarray Analysis
RNA was extracted from tumors of ROSA-CreER +/-/SSM2 +/-mice using TRIzol (invitrogen) and purified using RNeasy kit (Qiagen). Gene expression was measured using Affymetrix oligonucleotide-based GeneChip® microarray technology (Affymetrix, Santa Clara, CA). The microarray data has been uploaded to the GEO website (GEO accession: 14469). Further information on microarray analysis is included in the supplementary document
Results
Targeted expression of SYT-SSX2 in most tissue types is lethal
We previously reported generation of a mouse line (SSM2 mouse line) that expresses the human SYT-SSX2 fusion gene conditionally from the ROSA promoter in the presence of Cre recombinase (4). Expression of SYT-SSX2 is also linked to expression of the Enhanced Green Fluorescent marker protein (EGFP) via an Internal Ribosomal Entry Site (IRES) ( Figure 1A ). We previously reported that expression of SYT-SSX2 within Myf5-expressing myoblasts led to apoptosis, except in certain microenvironments where the SYT-SSX2 expressing cells appeared to be protected from apoptosis and thereby allowed progress towards neoplasia. Therefore, it appeared logical to assume that this dominant cytotoxic effect of SYT-SSX2 expression led to lethality in most breeding experiments with tissue specific Cre drivers. To further confirm this in-vitro in a more controlled environment, we harvested mouse embryonic fibroblasts (MEFs) from SSM2 +/-mice. As control, we also harvested MEFs from ROSA-YFP +/- (11) mice that expresses the Yellow Fluorescent Protein (YFP) from the ROSA locus in the presence of Cre.
These cells were exposed to 3µM of a modified Cre protein that has the protein-transductiondomain of HIV TAT protein fused to the N-terminus of Cre (TAT-CRE) (12) . Direct addition of such purified TAT-CRE protein to cultured cells allows for more rapid, stable, and uniform activation of Cre dependent loci than is possible by the more commonly used DNA mediated transfection procedures.
SYT-SSX2 +/-MEFs exposed to TAT-CRE ( SYT-SSX2 +/-fibroblasts (B) from SSM2 +/-embryos and control ROSA-YFP +/-fibroblasts (C) from ROSAY-YFP +/-embryos were cultured. SYT-SSX2 +/-and ROSA-YFP +/-fibroblasts were divided into two groups; those exposed to TAT-Cre protein at 3 µm concentration for 2 hours and those not exposed to TAT-Cre. By the second day, SYT-SSX2 +/-fibroblasts exposed to TAT-CRE (Ba and Bb) showed SYT-SSX2 expression based on EGFP induced fluorescence (Bb) while those not exposed to TAT-CRE (Bc and Bd) showed no fluorescence (Bd). Control ROSA-YFP +/-cells exposed to TAT-Cre (Ca and Cb) showed robust YFP expression (Cb) while those not exposed to TAT-CRE (Cc and Cd) showed no YFP expression (Cd).
Upon serially tracking the same zones, by day five SYT-SSX2 +/-fibroblasts exposed to TAT-CRE (Be and Bf) showed significantly less growth (Be) and very few EGFP expressing cells (Bf) while those not exposed to TAT-CRE showed robust growth (Bg) with no EGFP expression (Bh). Control ROSA-YFP +/-cells exposed to TAT-CRE continued to show robust growth (Ce) and YFP expression (Cf) while those not exposed to TAT-CRE showed robust growth (Cg) without YFP expression (Ch). All scale bars = 50 µm. 
Figure 4
Clustering result of various mouse tumors and normal skeletal muscle samples. The box highlights the similarity between tumors generated in R-CreER
+/-mice (green circles) and those generated in Myf5-Cre
+/-mice (red circles). Other tumors cluster in distinct groups based on their diagnostic similarity, while skeletal muscle samples cluster distinct from all tumors. Various tissues of adult R-CreER +/-/R-LacZ +/-mice did not show β-galactosidase staining in the absence of Tamoxifen (Ba to Bf) while intra-peritoneal injection of 0.1mg/gm Tamoxifen followed by β-galactosidase staining after one week revealed robust β-galactosidase expression in liver (Bg and Bm) and spleen (Bh and Bn), moderated expression in kidney (Bi and Bo) and heart (Bj and Bp), and sparse expression in lungs (Bk and Bq) and Skeletal muscle (Bl and Br). +/-/R-CreER +/-mice (n=7) and control mice comprising of SSM2 +/-, R-CreER +/-, and wild type (n=18) were injected intraperitoneally with one pulse of 0.1 mg/gm of Tamoxifen at 3 months of age. These mice were followed up and the percentage of mice surviving (y axis) was plotted against age (x axis). This reveals that that all SSM2 
